Waters Corporation (WAT) , a global analytics leader, has consistently made headlines in the bio-tech market. The corporation's Q1 Earnings signaled an
upward trend, leading major firms to raise their stock ratings and price targets, with Baird raising the figure to
$407 and KeyBanc rating the stock as
Overweight. Despite this, the corporation's high valuation has caused some concern. The recent opening of a
precision manufacturing facility in Longbridge, UK, and strong Q4 performance signaled optimism for its 2025 outlook. Yet, the stock nosedived due to a miss in the quarterly revenue guidance. Waters Corporation has continued to innovate, expanding its Bio HPLC Line and launching new software for improved lab-centric business intelligence. The
annual earnings, coupled with strong financial performance, resulted in the stock hitting a 52-week high of $420.32. However, quarterly earnings slightly missed expectations, creating a mixed outlook. With noteworthy strategic growth drivers, and a
positive SWOT analysis, the stock is ready for a potential growth burst.
Waters Corp WAT News Analytics from Thu, 05 May 2022 07:00:00 GMT to Tue, 08 Apr 2025 22:18:33 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 6
